This led to approval of the first GLP1-RA for treatment of type 2 diabetes (T2D) in 2005, followed by approval for obesity treatment in 2014 after its association with reduced food intake was established5. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.